Live Breaking News & Updates on Kepler University Hospital
Stay updated with breaking news from Kepler university hospital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase I study of the. ....
How critical is the situation in Austrian hospitals? thelocal.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelocal.at Daily Mail and Mail on Sunday newspapers.
Today in Austria: A roundup of the latest news on Thursday thelocal.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelocal.at Daily Mail and Mail on Sunday newspapers.
MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent high-grade gliomas (HGG), including glioblastoma multiforme (GBM). TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of Telix's lead therapeutic clinical programs and has been granted orphan drug designation in the U.S. and Europe. TLX101 targets L-type amino acid transporter 1 (LAT-1), typically over-expressed in many malignant tumours, including HGG/GBM. The IPAX-Linz study, which is being led by Professor Josef Pichlerat Kepler University Hospital in Linz, Austria, builds on data generated in the IPAX-1 study. The final results of the IPAX-1 study, reported in September 2022, demonstrated a favourable safety profile and encouraging preliminary therapeutic effect.[1] IPAX-Lin ....